(budesonide/glycopyrrolate/formoterol fumarate) Now Approved. Visit The Physician Site. Explore A New Approved Treatment Option. Be The First To Learn About BREZTRI. Now Approved. Prescribing Information. Register For Updates. Learn The Pronunciation.
MYCAPSSA® (octreotide) delayed-release oral capsules is the first and only FDA-approved oral somatostatin analog (SSA) for appropriate patients with acromegaly, providing effective and consistent biochemical control, while freeing patients from the burden of injections.
CYSTADROPS (cysteamine ophthalmic solution) 0.37% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.
Dojolvi is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Visit Official HCP Site to See if Evrysdi™ Could be an Option for Your Patients. Evrysdi Challenges. Evrysdi Education. Evrysdi Resources. Evrysdi Treatment. Types: Learn About Evrysdi, Clinical Trial Results, Safety and Efficacy, Potential Benefits.
HCPs - Learn About Now Approved BLENREP (belantamab mafodotin-blmf). View Boxed Warning.
Explore ENSPRYNG™ As A New Treatment Option For Your Patients. Contraindications. Prescribing Information. Safety Info. Dosing & Admin. Types: Financial Assistance, ENSPRYNG Access Solutions, Clinical Trial Data, Patient Resources.
FINTEPLA is a prescription medicine used to treat the seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA is a federally controlled substance (C-IV) because it contains fenfluramine. Keep FINTEPLA in a safe place to prevent misuse, abuse, and protect it from theft.
Helpful information for your patients. Get product information intended for healthcare professionals. Resources. About KALYDECO. Studies and Data.
Learn about FDA-approved Gimoti. See Safety and Boxed Warning. Get updates and read about Gimoti, a different formulation of metoclopramide. Prescribing Information. Press Release. Important Safety Info.
KESIMPTA® is FDA Approved. Download a Start Form Today. Visit Now to Learn More. Access PI and Start Resources for HCPs. Contact Us for Support. Enrollment Support. Official HCP Website. HCP Resources. FDA Approved. KESIMPTA® Safety Info.
INQOVI is the first and only oral hypomethylating agent (HMA) indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic ...
Learn More About MONJUVI, FDA-approved and Now Available. Visit the Official Site Now. Learn About Treatment. Treatment Calendar. Now Approved.
Visit The Official HCP Website for GAVRETO Information. Learn More Today. Safety Information. Registration Form. Patient Services. HCP Information. Patient Support. Dosing Information. Downloadable Resources. Healthcare Professionals. Prescribing Information.
Mayo Clinic and collaborators today reported safety data on the first 5,000 hospitalized patients transfused with investigational convalescent plasma as part of the Food and Drug Administration’s national Expanded Access Program (EAP) for COVID-19. The early indicators suggest experimental convalescent plasma is safe in treating severely ill patients. At this time, convalescent plasma is the on...
Qwo™ (collagenase clostridium histolyticum-aaes) Is Now FDA Approved. Check Out The Press Release & Sign Up For More Information From Endo Aesthetics Today. Official Product Site · Sign Up For Updates · Indication
(Brexucabtagene Autoleucel) Visit Site To Learn More & Read Important Warnings. Download The Medication Guide And Find Your Nearest Treatment Center. Important Warnings. Download Med Guide. Find A Center.
TEPEZZA is a prescription medicine for the treatment of Thyroid Eye Disease (TED), also known as Graves' Orbitopathy. See safety information.
Eli Lilly and Company
Mar 10th, 2021 - INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with CO...
Nov 1st, 2021 - When applied to chest and throat, temporarily relieves cough due to minor throat and bronchial irritations associated with the common cold On muscles and joints, temporarily relieves minor aches and painsCamphor: cough suppressant / topical analgesic Menthol: cough suppressant / topical analgesic Eucalyptus oil: cough suppressant